Table 1.

Sensitivity of MDK and AFP in patients with hepatocellular carcinomas according to different tumor size and BCLC stage

Tumor sizeBCLC stagea
≤2 cm2–5 cm>5 cm0–AB–C
Cutoff value(ng/mL)n (%)n (%)n (%)n (%)n (%)
MDK0.65424 (80.0%)88 (88.0%)107 (87.7%)108 (87.1%)113 (88.3%)
AFP2012 (40.0%)45 (45.0%)74 (60.6%)58 (46.7%)73 (57.0%)
AFP-22006 (20.0%)29 (29.0%)59 (48.4%)35 (28.2%)59 (46.1%)
Combined MDK and AFPb0.654; 2029 (96.6%)95 (95.0%)115 (94.3%)119 (95.9%)123 (96.1%)
Combined MDK and AFP0.654; 20027 (90.0%)93 (93.0%)113 (92.6%)115 (92.7%)120 (93.7%)

NOTE: Hepatocellular carcinomas in the learning cohort A (N = 252). n (%), total number of positive patients with percentage according to different cutoff values presented above.

  • aAccording to the BCLC (Barcelona Clinic Liver Cancer) staging system.

  • bPatients with AFP and/or MDK elevation in the serum were considered positive.